4CPS-162 Infliximab serum concentrations, antibody formation and clinical response in psoriatic patients

BACKGROUND: A large variability in biopharmaceutical kinetics exists between patients and even within a patient over time. Also, adequate thorough concentrations are linked to response in psoriasis. Therapeutic drug monitoring of biopharmaceuticals (i.e. infliximab–IFX) together with clinical respon...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur J Hosp Pharm
Main Authors: Colls, M, Padullés, N, Padullés, A, Notario, J, Bas, J, Fernández, C Mariño, Colom, H
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Group 2018
Assuntos:
Section 4: Clinical pharmacy services
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535484/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.253
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares